Testing a blood marker to guide personalized treatment after chemotherapy for triple-negative breast cancer

This study is testing whether adding Tislelizumab, an immunotherapy medication, to standard chemotherapy helps prevent triple-negative breast cancer from coming back after surgery. Researchers will use a special blood test to identify patients whose cancer is most likely to return, and then randomly assign some of them to receive the new medication while others receive standard care alone. The goal is to see if this personalized approach saves lives.

Triple-negative breast cancer is an aggressive type that is harder to treat and more likely to come back than other breast cancers. This trial exists because doctors want to find a way to identify patients at highest risk of relapse early and give them stronger treatment options — and this medication may help prevent the cancer from returning.